• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Analysts: Stryker might not be the only bidder for Novadaq

Analysts: Stryker might not be the only bidder for Novadaq

June 20, 2017 By Brad Perriello

Stryker acquires NovadaqStryker (NYSE:SYK) might not be the only firm in the running for Novadaq Technologies (TSE:NVDQ), according to analysts responding to Stryker’s $701 million bid for the Canadian fluorescence imaging company.

Mississauga, Ontario-based Novadaq yesterday agreed to the $11.75-per-share bid, which offers a 95.8% premium on NVDQ’s $6 closing price June 16. That agreement – and the high premium – was likely the result of a bidding process, according to Leerink Partners analysts Richard Newitter and Ravi Misra.

“We believe there was a competitive process for the asset, and the deal price likely reflects this on some level,” Newitter and Misra wrote yesterday in a note to investors.

And Canaccord Genuity analyst Jason Mills said the terms of the deal (a relatively low $21 million termination fee and a “right to match” provision) indicate that other medtech players like Medtronic (NYSE:MDT), Johnson & Johnson (NYSE:JNJ) or Intuitive Surgical (NSDQ:ISRG) could emerge as Novadaq suitors.

“While competitive bids are usually low probability in medtech, we think the potential is a bit higher in this case, as we believe the NVDQ asset would fit very well strategically within any of the aforementioned companies,” Mills wrote.

Newitter and Misra noted that Intuitive worked with Novadaq to integrate the Spy technology into its Firefly imaging system.

“This collaboration runs through 2021 and we do not expect SYK’s acquisition of NVDQ to impact this agreement/collaboration,” they wrote.

The expected 3¢-to-5¢ dilution to adjusted earnings per share this year could be topped, Newitter and Misra added, “given SYK’s stringent M&A criteria (ROIC>[weighted average cost of capital] within 3 years).”

“[W]e think it’s highly likely the company will remain focused on achieving (possibly beating) communicated accretion targets. We caught up with mgmt who noted to us that it views the technology as being transformative to the endoscopic division in the same way that Mako (acquired in 2012) was transformative to the orthopedic division,” they wrote.

“In our view, this is a quintessential SYK M&A transaction. The company has completed over 50 deals in the last decade ranging from between few hundred million to multibillion dollar transactions. Many of these deals have had similar characteristics – i.e., top-line growth acceleration prospects via a new product lines or adjacencies, slight near-term dilution and accretive within 1-2 years. We believe NVDQ falls into this genre. As well, the deal further validates the advanced visualization segment, which is an area on which other companies in our universe have increasingly been focused and successfully targeting (i.e. ISRG [OP]) or beginning to target (i.e. IVTY [OP]) through partnerships and/or internal development initiatives,” Newitter and Misra wrote.

Filed Under: Imaging, Mergers & Acquisitions, Wall Street Beat Tagged With: Intuitive Surgical, Johnson and Johnson, Medtronic, Novadaq, Stryker

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy